Tempus May 6, 2022 Tempus to Provide NGS Cancer Tests to US Department of Veterans Affairs Aug 17, 2021 Tempus Submits PMA Application for Tumor Profiling Assay to FDA Jul 2, 2021 In Brief This Week: Foundation Medicine, Myriad Genetics, Immunovia, Biocept, and More Feb 4, 2021 In Brief This Week: Quidel, Ortho Clinical Diagnostics, Hologic, Guardant Health, and More Jan 13, 2021 Tempus, A2 Biotherapeutics Partner to Develop CDx for Therapy Targeting Loss of Heterozygosity Jan 12, 2021 JP Morgan Healthcare Conference 2021, Day One: Roche, Guardant, Hologic, Thermo Fisher, and More Dec 10, 2020 Tempus Raises $200M in Series G2, Inks Oncology Testing Collaboration With Bayer Nov 24, 2020 Tempus Gets CE Mark for xT Tumor Sequencing Assay Nov 16, 2020 Tempus, Yale School of Public Health Partner to Update Saliva-Based Coronavirus Test Oct 14, 2020 Tempus Enters Infectious Disease Market With Large-Scale COVID-19 Testing, Data Initiative Oct 2, 2020 Tempus, Alimetrix Molecular Coronavirus Tests Get FDA Emergency Use Authorization Feb 26, 2020 Congressional Caucus Working to Raise Personalized Medicine Awareness Among Legislators Premium Feb 6, 2020 Despite Barriers, Labs Starting to Report Suspected Cancer Risk Mutations Seen in Tumor Testing Dec 13, 2019 Tempus Acquires Commercial Lab, Precision Medicine Services Provider Akesogen Sep 25, 2019 IPO Window Wide Open for Dx, Genomics Companies Premium Breaking News In Brief This Week: NIH, Thermo Fisher Scientific, Biocept, Castle Biosciences, Biodesix Biological Dynamics Taps Two Firms to Study Utility, Economics of Pancreatic Cancer Detection Test FDA Grants EUAs to Lucira Health Molecular COVID/Flu Test, Azure Biotech, CorDx COVID Antigen Tests Biocare Medical Acquires Empire Genomics Meridian Bioscience Fiscal Q4 Revenues Fall 14 Percent, Full-Year Revenues Grow 5 Percent Japanese Consortium Launches Study to Evaluate Utility of Blood-Based Alzheimer's Markers
